Day Gain | ||
Gain | ||
Market Val | ||
Costs | ||
Cash | ||
Portfolio | ||
Realized | ||
Dividend |
Algert Global LLC Purchases Shares of 40,626 GameStop Corp. (NYSE:GME) | news.google.com • |
Can The GameStop Stock Hold Above The 50-Month-EMA Support? | news.google.com • |
Meme stock roller coaster: What’s next for GME, AMC, and DJT | news.google.com • |
AMC Slashes Debt By $153 Million But Stock Dithers; Are Meme Stocks A Buy Now? | news.google.com • |
Meme Stocks: What They Are and 5 Top Stocks for October 2024 | news.google.com • |
3 Meme Stocks to Monitor After Summer Rally | schaeffersresearch.com • |
Date | For | Estimate | Reported | Surprise | surprise % |
---|---|---|---|---|---|
2024-09-10 | 2024-07 | -0.01 | 0.01 | 0.02 | 200.00% |
2024-06-07 | 2024-04 | -0.1 | -0.12 | -0.02 | -20.00% |
2024-03-26 | 2024-01 | 0.25 | 0.22 | -0.03 | -12.00% |
2023-12-06 | 2023-10 | -0.12 | N/A | N/A | N/A |
2023-09-06 | 2023-07 | -0.15 | -0.03 | 0.12 | 80.00% |
2023-06-07 | 2023-04 | -0.17 | -0.14 | 0.03 | 17.65% |
Date | Firm | Action | From | To |
---|---|---|---|---|
2023-09-06 | Wedbush | Upgrade | Underperform | Underperform |
2023-08-31 | Wedbush | Upgrade | Underperform | Underperform |
2023-06-07 | Wedbush | Upgrade | Underperform | |
2023-06-01 | Wedbush | Upgrade | Underperform | |
2023-03-15 | Wedbush | Upgrade | Underperform | Underperform |
2022-07-21 | Wedbush | Upgrade | Underperform |
Date | Name | Relation | Quantity | Description |
---|---|---|---|---|
2023-09-07 | ATTAL ALAIN | Director | 562.46K | Purchase |
2024-07-07 | CHENG LAWRENCE | Director | 0.00 | Purchase |
2023-06-08 | COHEN RYAN | Officer, Director and Beneficial Owner | 0.00 | Purchase |
2023-06-14 | GRUBE JAMES | Director | 23.86K | Stock Award(Grant) |
2024-10-01 | MOORE DANIEL WILLIAM | Officer | 37.28K | Sale |
2023-07-09 | PATEL NIR VINAY | Chief Operating Officer | 1.00M | Sale |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-06-29 | Vanguard Group Inc | 24.94M | 604.74M | 8.17% |
2023-06-29 | Blackrock Inc. | 21.68M | 525.79M | 7.10% |
2023-06-29 | State Street Corporation | 7.45M | 180.68M | 2.44% |
2023-06-29 | Geode Capital Management, LLC | 3.77M | 91.54M | 1.24% |
2023-06-29 | Bank Of New York Mellon Corporation | 2.12M | 51.41M | 0.69% |
2023-06-29 | Charles Schwab Investment Management, Inc. | 2.07M | 50.27M | 0.68% |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-09-29 | iShares Core S&P Midcap ETF | 8.39M | 138.06M | 2.75% |
2023-06-29 | Vanguard Total Stock Market Index Fund | 8.07M | 195.65M | 2.64% |
2023-06-29 | Vanguard Small-Cap Index Fund | 6.69M | 162.16M | 2.19% |
2023-06-29 | Vanguard Small Cap Value Index Fund | 4.63M | 112.37M | 1.52% |
2023-06-29 | Vanguard Extended Market Index Fund | 3.50M | 84.79M | 1.15% |
2023-08-30 | SPDR S&P Mid Cap 400 ETF Trust | 2.12M | 39.31M | 0.69% |
Dividend | Date |
---|---|
0.38 | 2019-03-14 |
0.38 | 2018-12-10 |
0.38 | 2018-09-17 |
0.38 | 2018-06-11 |
0.38 | 2018-03-02 |
0.38 | 2017-11-30 |
Split | Date |
---|---|
4 : 1 | 2022-07-22 |
2 : 1 | 2007-03-19 |
-
-
-
-
They have re-shorted their position in hopes that the “media campaign” they have “initiated against public stock holders of $GME and $AMC” will scare them into selling their position.
LISTEN!!! THE TRADING VOLUME DOES NOT SHOW ANY OF THEIR SHORT POSITION BEING COVERED.
Look at the data, if 120% of the stock were to have been bought back by the HEDGE FUNDS, WE WOULD SEE THE VOLUME SHOW UP IN THE TRADING VOLUME....
THEY HAVE NOT COVERED A THING, THE ARE HOLDING THEIR SHORT POSITION UNTIL THEY “HAVE TO” COVER, WHICH IS TODAY AND THURSDAY.
I AM BUYING MORE OF BOTH, at a wonderful discount!! Thank you hedgies, I appreciate the extra return you are giving me the opportunity to increase due to your inability to realize when you have lost.
THIS IS HOW WALLSTREET HAS BEEN FOR YOO LONG. I DONT LIKE MY MONEY BEING USED TO MAKE SOMEONE ELSE RICH. I’ve had enough, I’m all I’m!
-
Buying at $13/share before next Friday
-
-
Get on BNGO before too late
Saphyr Study Is First to Analyze Cancer Regulation at Level of Single DNA Molecules, Opens Promising New Avenue of Cancer Research
Publication on novel Saphyr based method to analyze DNA methylation in cancer genomes enables new field of cancer research and drug target discovery
Bionano Genomics
February 02, 2021 08:00 ET
SAN DIEGO, Feb. 02, 2021 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO), announced today the publication of a study that measured DNA methylation, the chemical modification of the DNA that controls gene regulation, of the various regions regulating cancer genes on single DNA molecules. The study led by Dr. Yuval Ebenstein at the Tel Aviv University found that optical genome mapping (OGM) with Bionano’s Saphyr system combined with a custom labeling method developed by the scientists was capable of analyzing regulatory regions that work together to turn cancer genes on and off over distances of hundreds of thousands of basepairs. The ability to measure these relationships on single DNA molecules is something that was previously impossible. Only Saphyr can detect these long-distance connections in methylation profiles because it’s the only technology that can generate such long-range, single molecule data at high throughput and coverage.While most of the important information in our genome is encoded in the sequence and the structural organization of the sequence, the regulation of genes is partially registered through chemical labels attached to the DNA. These chemical labels, called DNA methylation, can turn genes on and off at specific time points and in certain tissues. A normal cell can only become cancerous and grow excessively by making multiple changes to the genome and the way it is regulated. These changes include single nucleotide variations, structural variations and changes to DNA methylation patterns that can happen to the actual cancer gene, to the promoter region that switches the gene on and off, or to enhancer regions that can be hundreds of thousands of basepairs removed from the cancer gene. Studying these methylation patterns has been difficult or impossible because current methods only allow you to measure values averaged over dozens or hundreds of cells. To fully understand how cancer genes are turned on and off, it is important to measure the methylation status of a gene, its promoter, and its enhancers on individual, single molecules, which is impossible with short-read or long-read sequencing because their read lengths are insufficient.
The study by Dr. Ebenstein is the first to systematically analyze more than one hundred thousand promoter-enhancer pairs up to 200,000 basepairs apart, on millions of single molecules. This large dataset enabled them to correctly distinguish between normal and tumor cells with an error rate smaller than 1%.
Yuval Ebenstein, PhD, commented: “Long methylation reads at such high coverage just never existed before, mostly because Saphyr produces the highest fraction of the longest reads compared to any other platform. This dataset allows us to analyze long range information on the single-molecule level, which opens up a whole new avenue for complex disease specific epigenetic biomarkers. This study can be dramatic for early cancer diagnostics where the normal and cancer cells have a very similar genetic background but the extreme changes in enhancer methylation distinguish the cancer cells. This data may for the first time allow us to discover new biomarkers and point to novel drug targets in places of the genome where no one has looked before.”
-
This will end around $60-$80 today at best.
-
This is most likely the highest you will ever see this stock again!
-
Wow!!!! This is dropping like the titanic.
-
Saphyr Study Is First to Analyze Cancer Regulation at Level of Single DNA Molecules, Opens Promising New Avenue of Cancer Research
Publication on novel Saphyr based method to analyze DNA methylation in cancer genomes enables new field of cancer research and drug target discovery
Bionano Genomics
February 02, 2021 08:00 ET
SAN DIEGO, Feb. 02, 2021 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO), announced today the publication of a study that measured DNA methylation, the chemical modification of the DNA that controls gene regulation, of the various regions regulating cancer genes on single DNA molecules. The study led by Dr. Yuval Ebenstein at the Tel Aviv University found that optical genome mapping (OGM) with Bionano’s Saphyr system combined with a custom labeling method developed by the scientists was capable of analyzing regulatory regions that work together to turn cancer genes on and off over distances of hundreds of thousands of basepairs. The ability to measure these relationships on single DNA molecules is something that was previously impossible. Only Saphyr can detect these long-distance connections in methylation profiles because it’s the only technology that can generate such long-range, single molecule data at high throughput and coverage.While most of the important information in our genome is encoded in the sequence and the structural organization of the sequence, the regulation of genes is partially registered through chemical labels attached to the DNA. These chemical labels, called DNA methylation, can turn genes on and off at specific time points and in certain tissues. A normal cell can only become cancerous and grow excessively by making multiple changes to the genome and the way it is regulated. These changes include single nucleotide variations, structural variations and changes to DNA methylation patterns that can happen to the actual cancer gene, to the promoter region that switches the gene on and off, or to enhancer regions that can be hundreds of thousands of basepairs removed from the cancer gene. Studying these methylation patterns has been difficult or impossible because current methods only allow you to measure values averaged over dozens or hundreds of cells. To fully understand how cancer genes are turned on and off, it is important to measure the methylation status of a gene, its promoter, and its enhancers on individual, single molecules, which is impossible with short-read or long-read sequencing because their read lengths are insufficient.
The study by Dr. Ebenstein is the first to systematically analyze more than one hundred thousand promoter-enhancer pairs up to 200,000 basepairs apart, on millions of single molecules. This large dataset enabled them to correctly distinguish between normal and tumor cells with an error rate smaller than 1%.
Yuval Ebenstein, PhD, commented: “Long methylation reads at such high coverage just never existed before, mostly because Saphyr produces the highest fraction of the longest reads compared to any other platform. This dataset allows us to analyze long range information on the single-molecule level, which opens up a whole new avenue for complex disease specific epigenetic biomarkers. This study can be dramatic for early cancer diagnostics where the normal and cancer cells have a very similar genetic background but the extreme changes in enhancer methylation distinguish the cancer cells. This data may for the first time allow us to discover new biomarkers and point to novel drug targets in places of the genome where no one has looked before.”
Erik Holmlin, PhD, CEO of Bionano Genomics commented: “While Bionano Genomics is laser focused on bringing comprehensive, whole genome structural variation detection to the clinic, scientists around the world are pushing the boundaries of what our single molecule analysis system Saphyr can do. Dr. Ebenstein’s team has developed a novel application of our technology that contributes to solving unique scientific questions. The epigenetic regulation of cancer genes through DNA methylation of its promoters and enhancers has been difficult or impossible to study with current methods that are limited by short read lengths. We are excited about the possibilities for discoveries of novel diagnostics and treatments for cancer that this application enables.”
The publication is available at https://www.biorxiv.org/content/10.1101/2021.01.28.428654v1
-
If you fall for their lies, you are a 🧻 bitch. Think about it, they manipulate the price down, you sell out of fear and they take a smaller hit when they start to cover their short position. This is going to go ballistic in the next couple of days.
I personally am holding what I have and buying more at this discount today!
-
Today WSB, Reddit and Retards got flushed like a turd. The happiest moment of my life. Burn them!!!! Let the lesson be learned once and for all. Now go to your daddies and ask them for a dollar to buy your favorite lollipop and suck on it
-
Good luck to whoever brought at 300s,
-
-
-
$GME this isn’t them driving down the price. It’s Asian (AH) and European (PM) losing faith in the stock and taking profits before this is worthless. Get out before it’s too late
-
-
Algert Global LLC Purchases Shares of 40,626 GameStop Corp. (NYSE:GME)
news.google.com • -
Can The GameStop Stock Hold Above The 50-Month-EMA Support?
news.google.com • -
Meme stock roller coaster: What’s next for GME, AMC, and DJT
news.google.com • -
Meme Stocks: What They Are and 5 Top Stocks for October 2024
news.google.com • -
3 Meme Stocks to Monitor After Summer Rally
schaeffersresearch.com • -
"No Coaches, No Players" in Gamestop's (GME) Leadership
youtube.com • -
GameStop Completes At-The-Market Equity Offering Program
globenewswire.com • -
GameStop CEO Ryan Cohen to pay $1M fine over Wells Fargo stock purchases
proactiveinvestors.com • -
This tactic could improve GameStop's performance, analyst says
marketwatch.com • -
GameStop Stock Breaches $20 After Revenue Whiff
schaeffersresearch.com • -
GameStop price target cut as analyst cites retailer's lack of strategy
marketwatch.com • -
GameStop: Earnings Won't Save It, Dilution Points to Trouble
marketbeat.com • -
GameStop in danger: Can GME stock hold the $20 mark?
finbold.com • -
Watch These GameStop Price Levels as Stock Plummets
investopedia.com •